Loading...
Market
What will be the outcome of the antibody prasinezumab trials influenced by Eliezer Masliah's research by December 31, 2024?
2
Eliezer Masliah•National Institute on Aging•NIA•National Institutes of Health•NIH•Science Magazine•Masliah•Western•Alzheimer•Parkinson•FDA
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Published trial results and peer-reviewed journals
Story
NIH's Eliezer Masliah Dismissed After 132 Papers Found with Manipulated Images in Alzheimer's and Parkinson's Research
Sep 26, 2024, 02:56 PM
Eliezer Masliah, a prominent neuroscientist and former head of the neuroscience division at the National Institute on Aging (NIA) within the National Institutes of Health (NIH), has been dismissed after an investigation reported by Science Magazine found he engaged in scientific misconduct. The investigation revealed that Masliah manipulated hundreds of images, including scores of falsified Western blots, in his research on Alzheimer's and Parkinson's diseases, with 132 of his papers containing suspect images. This misconduct raises concerns about the validity of decades of research that have influenced grants, FDA approvals, and clinical trials, potentially undercutting the science behind several drugs. Notably, his work led to trials of the antibody prasinezumab, which demonstrated no effect on measures of Parkinson’s disease progression in a 2022 paper published in the New England Journal of Medicine.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
No significant impact • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%